The company had earlier raised $15 million from UHNI, pharma founders and US-based VC funds.
Immunol Therapeutics is working on developing its own pipeline of chimeric antigen receptor T-cell (CAR-T) therapy and other cellular immunotherapies for the management and treatment of cancer.
It has entered Phase II human trials with its program ‘Imagine’.
“We are not only testing adults but also children with blood cancers,” said Arun Anand, director and chief operating officer, Immunal Therapeutics. “This therapy has shown remarkable results globally and is the need of the hour in India.”
Founded in 2019 by
Founder and Chairperson Kiran Mazumdar-Shaw, Indian-American physician and author Siddhartha Mukherjee, and Kush Parmar, Managing Partner of Lifesciences venture capital firm 5AM Ventures, Immunal Therapeutics cell and gene therapy programs, exclusively with clinical data, affordable prices in India want to bring. cost.
Find stories that interest you
Mazumdar Shaw told ET that it will use the funds to further its development pipeline and scale.
Immunel Therapeutics did not disclose its valuation after the latest funding round, which also saw participation from other existing investors.
In 2021, the company established the first cGMP-approved integrated cell therapy development and manufacturing facility at Mazumdar-Shaw Cancer Center in Narayana Health City, Bengaluru.
CAR-T treatments, previously not available in India, have shown promising results for patients who have exhausted all other modalities of treatment in a range of blood cancers. These treatments are available internationally for over $350,000 per dose.
Immunal Therapeutics said the Imagine trial is the first step towards bringing such treatments with global quality and clinical data at affordable rates to patients in India.
Mazumdar Shaw said, “This milestone is significant in building an ecosystem to accelerate and make cell therapy accessible to patients in India, at par with global standards at an affordable and disruptive cost.” “Personalized cell therapies are at their worldwide debut and we have the opportunity to make a difference through partnerships and cutting-edge innovation.”